CN107961234B

CN107961234B - Application of Ramosissimarin in preparation of medicine for treating rheumatoid arthritis

Info

Publication number: CN107961234B
Application number: CN201810043917.8A
Authority: CN
Inventors: 李娟�; 姚遥; 李玮琦
Original assignee: Ningxia Medical University
Current assignee: Ningxia Medical University
Priority date: 2018-01-17
Filing date: 2018-01-17
Publication date: 2020-08-18
Anticipated expiration: 2038-01-17
Also published as: CN107961234A

Abstract

The invention relates to application of a compound Ramosissimarin in preparation of a medicine for treating rheumatoid arthritis. Pharmacological experiments prove that ramosissimarin has obvious activities of inhibiting the proliferation of rheumatoid arthritis synovial cells and inducing the apoptosis of the rheumatoid arthritis synovial cells for the first time, and can be used for preparing medicines for preventing and/or treating rheumatoid arthritis, so that ramosissimarin has high clinical application value and development prospect. The invention discloses application of a compound ramosissimarin in preparation of a medicine for resisting rheumatoid arthritis. The structural formula of Ramosissimarin is shown as a formula I, and the Ramosissimarin is obtained by separating from branches of Tamarix polycarpa. The invention discovers for the first time that ramosissimarin can obviously inhibit the proliferation of rheumatoid arthritis synovial cells and induce the apoptosis of the rheumatoid arthritis synovial cells.

Description

Application of Ramosissimarin in preparation of medicine for treating rheumatoid arthritis

Technical Field

The invention relates to application of a compound Ramosissimarin in preparation of a medicine for treating rheumatoid arthritis.

Background

Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease mainly characterized by arthropathy, the pathogenesis of which is unknown at present, and the clinical thinking that the pathogenesis of RA is mainly caused by allergic reaction due to autoimmune dysfunction of patients, so that anti-inflammatory cells deteriorate and denature and deposit in joint parts and joint tissues are deformed and disabled. According to investigation, the incidence rate of RA in the world is about 1-2%, the total number of RA patients in China is over 400 ten thousand, and the incidence rate is still on the rise.

At present, non-steroidal anti-inflammatory drugs (diclofenac, aspirin and the like) and immunosuppressants (6-mercaptopurine and the like) are mainly used for treating rheumatoid arthritis, but the drugs have obvious adverse reactions, such as peptic ulcer caused by the fact that the former damages gastrointestinal mucosa, and infection is easily induced by the latter. Therefore, research and development of safe and effective drugs for treating rheumatoid arthritis is an urgent task at present.

In recent years, scholars at home and abroad make extensive and intensive research on the aspect of treating RA by using plant medicines, and discover that a plurality of natural medicines such as erycibe glycoside, total glucosides of paeony, poison vine and the like have better RA treatment effect. Therefore, the safe and efficient RA treatment medicine has wide prospect from the botanical medicine.

Disclosure of Invention

The invention aims to provide application of a compound Ramosissimarin in preparation of a medicine for treating rheumatoid arthritis, which has the remarkable activities of inhibiting the proliferation of rheumatoid arthritis synovial cells and inducing the apoptosis of the rheumatoid arthritis synovial cells and can be used for preparing the medicine for preventing and/or treating the rheumatoid arthritis.

Application of Ramosissimarin in preparing a medicament for preventing or treating rheumatoid arthritis, wherein the structural formula of the compound Ramosissimarin is as follows:

the application of Ramosissimarin in preparing a medicament for inhibiting the proliferation of rheumatoid arthritis synovial cells, wherein the structural formula of the compound Ramosissimarin is as follows:

pharmacological experiments prove that ramosissimarin has obvious activities of inhibiting the proliferation of rheumatoid arthritis synovial cells and inducing the apoptosis of the rheumatoid arthritis synovial cells for the first time, and can be used for preparing medicines for preventing and/or treating rheumatoid arthritis, so that ramosissimarin has high clinical application value and development prospect.

The invention discloses application of a compound ramosissimarin in preparation of a medicine for resisting rheumatoid arthritis. The structural formula of Ramosissimarin is shown as a formula I, and the Ramosissimarin is obtained by separating from branches of Tamarix polycarpa. The invention discovers for the first time that ramosissimarin can obviously inhibit the proliferation of rheumatoid arthritis synovial cells and induce the apoptosis of the rheumatoid arthritis synovial cells. Therefore, the compound can be used for preparing a medicament for preventing and/or treating rheumatoid arthritis, and has higher clinical application value and development prospect.

Drawings

FIG. 1 is a graph showing the statistical results of inhibition of proliferation of synovial cells in rheumatoid arthritis by ramosissimarin at various concentrations in example 1 of the present invention;

FIG. 2 is a graph showing the statistical results of the promotion of synovial cell apoptosis in rheumatoid arthritis by ramosissimarin at different concentrations in example 2 of the present invention.

Detailed Description

The invention provides application of a compound ramosissimarin in inhibition of rheumatoid arthritis synovial cell proliferation and prevention and/or treatment of rheumatoid arthritis.

The structural formula of the compound ramosissimarin related by the invention is shown as a formula I:

the compound is obtained by separating from Tamarix ramosissima Ledeb (Zingiberaceae. Salix purpurea chemical composition research [ D ]. Ningxia medical university, 2016). The multi-branch tamarix chinensis is an excellent tree species for wind-proof sand-fixation plants and saline-alkali land afforestation, and is widely distributed in northwest areas of China and rich in resources.

The application of ramosissimarin provided by the invention comprises two aspects: 1) the application of the compound in preparing products for preventing and/or treating rheumatoid arthritis; 2) the application of the compound in preparing products for inhibiting the proliferation of rheumatoid arthritis synovial cells.

The ramosissimarin can obviously inhibit the proliferation of rheumatoid arthritis synovial cells and induce the apoptosis of the rheumatoid arthritis synovial cells, and can be used for preparing a medicament for preventing and/or treating rheumatoid arthritis.

In addition, the following products were prepared with ramosissimarin as an active ingredient: 1) products for the prevention and/or treatment of rheumatoid arthritis; 2) the product for inhibiting the proliferation of synovial cells in rheumatoid arthritis also belongs to the protection scope of the invention.

The agent for preventing and/or treating rheumatoid arthritis and the agent for inhibiting proliferation of synovial cells of rheumatoid arthritis in the present invention can be introduced into the body such as muscular, intradermal, subcutaneous, intravenous, mucosal tissue by injection, permeation, absorption, physical or chemical-mediated method; or mixed or coated with other materials and introduced into body.

If necessary, one or more pharmaceutically acceptable carriers can be added into the medicine. The carrier includes diluent, excipient, filler, binder, wetting agent, disintegrating agent, absorption enhancer, surfactant, adsorption carrier, lubricant, etc. which are conventional in the pharmaceutical field.

The above medicine can be made into various forms such as injection, tablet, powder, granule, capsule, oral liquid, paste, cream, etc. The medicines in the above various dosage forms can be prepared according to the conventional method in the pharmaceutical field.

In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

Example 1:

inhibition of rheumatoid arthritis synovial cell proliferation by Ramosissimarin

Cell: human rheumatoid arthritis synovial cells (RA-FLS);

medicine preparation: ramosissimarin;

the method comprises the following steps: resuscitation of RA-FLS

And (3) quickly taking out the RA-FLS cryopreservation tube from the liquid nitrogen tank, putting the RA-FLS cryopreservation tube into a constant-temperature water bath kettle with the temperature of 37 ℃, and continuously shaking to accelerate cell thawing. And after the thawing is completed, transferring the RA-FLS suspension in the freezing storage tube to a 10mL sterile centrifuge tube in a super clean bench by using a pipettor, and centrifuging for 5min at the rotating speed of 1000 r/min. Pouring out supernatant, adding 5mL of complete culture solution, continuously blowing to obtain uniform cell suspension by using a pipette, inoculating RA-FLS into a 25mL cell culture bottle, and culturing in a cell culture box with the conditions of 37 ℃ and CO₂The concentration was 5%. After 24h, the growth of RA-FLS was observed under a microscope, and when cells were found to be adherent, triangular and irregular fusiform, the tableThe growth of bright cells was good.

Passage of RA-FLS

When the RA-FLS grows to be about 80 percent of the bottom of the whole cell culture bottle by adherence under a microscope, cell passage can be carried out. Pouring out the original culture solution in the culture bottle, and washing with PBS for 2 times, so as to clean the original culture solution and avoid affecting cell digestion; adding 0.25% trypsin digestive juice for digestion, observing the digestion condition of RA-FLS under a microscope, adding a proper amount of Fetal Bovine Serum (FBS) to stop digestion when most cells are rounded under the microscope, then adding a certain amount of complete culture solution into a culture bottle, and repeatedly blowing the inner wall of the culture bottle by using a sterile pipette to form uniform cell suspension; counting the cells by using a cell counting plate, inoculating RA-FLS into 2 new culture bottles after counting, adding a proper amount of complete culture solution, and putting the culture bottles into a cell culture box for culture, wherein the conditions of the culture box are set to 37 ℃, the concentration of CO2 is 5 percent, namely subculturing in a one-to-two mode.

Determination of cell inhibition Rate by MTT method

Taking a proper amount of ramosissimarin and DMEM to prepare culture solutions of 0.01, 0.1, 1, 5 and 10 mu M respectively, taking RA-FLS in logarithmic phase, pouring out original culture solution in a culture bottle, washing for 2 times by PBS, adding 0.25% trypsin digestive juice for digestion, observing the digestion condition of RA-FLS under a microscope, adding a proper amount of FBS to stop digestion when most cells are rounded under a microscope, adding a certain amount of culture solution into the culture bottle, continuously blowing the inner wall of the culture bottle by using a sterile straw to form uniform cell suspension, counting by using a cell counting plate, adjusting the cell concentration to be 1 × 10 by using the culture solution, and then adding the culture solution into the culture bottle⁵Inoculating RA-FLS into 96-well sterile cell culture plate (100 μ L per well), culturing in cell culture box (temperature 37 deg.C, CO)₂The concentration was 5%. After 24h incubation, the 96-well plate is divided into 6 groups (namely blank control group, 0.01, 0.1, 1, 5 and 10 mu M drug group, each group has 6 multiple wells), the stock culture solution in the wells is sucked, the same amount of DMEM and the drug-containing culture medium with different concentrations are respectively added, and the mixture is put into a cell incubator for intervention. After 24h and 48h of intervention, 20. mu.L MTS, 37 h was added to each wellIncubating for 1.5h at the temperature of room temperature, measuring the absorbance of each hole at the wavelength of 540nm by using an enzyme-linked immunosorbent assay instrument, and calculating the inhibition rate of each group of cells.

The calculation formula is as follows:

the cell inhibition rate/% (1-blank control group OD value/each concentration drug group OD value) × 100%

As a result: the ramosissimarin with the concentration of 0.1-10 mu M can obviously inhibit the proliferation of RA-FLS, and the inhibition effect is enhanced along with the increase of the drug concentration.

Example 2:

promotion effect of Ramosissimarin on rheumatoid arthritis synovial cell apoptosis

Cell: human rheumatoid arthritis synovial cells (RA-FLS);

medicine preparation: ramosissimarin;

the method comprises the following steps: resuscitation of RA-FLS

Same as in example 1.

Passage of RA-FLS

Same as in example 1.

Determination of apoptosis by TUNEL method

The fragmentation of chromosomal DNA during apoptosis is a gradual, staged process, with chromosomal DNA first being degraded into large fragments of 50-300kb by endogenous nucleolytic enzymes. Then about 30% of the chromosomal DNA is in Ca²⁺And Mg²⁺Under the action of the dependent endonuclease, nucleosome units are cut off randomly to form a nucleosome DNA polymer of 180-200 bp. Detection of apoptotic cells can be carried out by labeling a derivative of deoxyribonucleotide and fluorescein, peroxidase, alkaline phosphorylase or biotin to the 3 '-end of DNA by deoxyribonucleotide terminal transferase (TdT) at the 3' -OH end of DNA double-strand break or a series of DNA ends resulting from nicking only one strand, which is generally called as deoxyribonucleotide terminal transferase-mediated nick end labeling (TUNEL).

A proper amount of ramosissimarin is prepared into culture solutions of 0.1 and 1 mu M respectively by DMEM, RA-FLS cells are incubated in blank and drug-containing culture solutions for 48h, and fixed for 30min by using 4% paraformaldehyde at room temperature. Rinsing with Phosphate Buffer Solution (PBS) for 3 times, adding cell membrane permeation solution (0.1% sodium citrate, 0.1% TritonX-100) and acting for 2 min. The labeling reaction was carried out at 37 ℃ for 1h using deoxyribonucleotide terminal transferase (TdT) and biotin-11-deoxyuridine triphosphate (biotin-11-dUTP). Cell morphology was observed using a fluorescence microscope and apoptosis index was calculated.

The calculation formula is as follows:

apoptosis index/% (number of apoptotic cells/1000 in 1000 cells) × 100%.

In the application of the Ramosissimarin in preparing the medicine for treating rheumatoid arthritis, the dosage of the Ramosissimarin is 0.1-0.5 mg/kg/day, and the Ramosissimarin is orally taken.

Claims

The use of Ramosissimarin as the sole active ingredient in the manufacture of a medicament for the prevention or treatment of rheumatoid arthritis, wherein the compound Ramosissimarin has the following structural formula:
the application of Ramosissimarin as a sole active ingredient in preparing a medicament for inhibiting the proliferation of rheumatoid arthritis synovial cells, wherein the structural formula of the compound Ramosissimarin is as follows: